The sources used here report no trial of hydroquinone 8%. They do include a systematic review of ochronosis case reports that concluded hydroquinone in concentrations above 4% and in treatment courses longer than 3 months may be associated with new-onset ochronosis. They also include a DailyMed listing for a hydroquinone 8% / tretinoin 0.025% emulsion with the marketing status unapproved drug other.
What the systematic review found
The 2022 review in the International Journal of Dermatology selected 56 articles with a total of 126 patients with hydroquinone-associated ochronosis and excluded articles that were non-case studies. It reported that ochronosis was most frequently reported with unknown and hydroquinone concentrations greater than 4% (32.5 and 35.7% cases, respectively), and that median duration of use was 5 years. It also reported only four cases with courses 3 months or shorter and eight cases with use 1 year or less.
The authors' stated conclusion is that concentrations above 4% and courses longer than 3 months "may be associated with" new-onset ochronosis. This was a review of case reports, so every patient already had ochronosis. Case reports cannot show cause and effect, and this design cannot show how many people used a given strength without developing it.
What each source says about strength
| Question | What the source says |
|---|---|
| What does the 2015 review of exogenous ochronosis say? | A review states that, although considered uncommon, the incidence will likely continue to increase with the use of skin-lightening agents above the FDA's recommended over-the-counter concentrations without the guidance of a dermatologist. This is the review's expectation, not a trial result. |
| What does a dermatologist's 2007 review report? | Written in response to the FDA's proposed ban, the review reported an incidence of exogenous ochronosis in the United States of 22 cases in more than 50 years, in a literature review involving over 10,000 exposures under careful clinical supervision. The abstract does not break this down by hydroquinone concentration. |
| Does any abstract mention a 5% formula? | The abstract of a Q-switched ruby laser versus triple combination cream trial in solar lentigines (per its title) states that a triple combination of hydroquinone 5%, tretinoin 0.03%, and dexamethasone 0.03% is often used for skin-lightening. This is a background sentence, not a result. |
| What does the DailyMed listing for a hydroquinone 8% / tretinoin 0.025% emulsion show? | The listing names a 30gm package, shows the marketing status unapproved drug other, and states that the drug has not been found by FDA to be safe and effective and that the labeling has not been approved by FDA. |
| What does DailyMed show for a prescription hydroquinone 4% cream label? | The record shows the same marketing status, unapproved drug other, and the same FDA disclaimer. |
Approved, unapproved and compounded
The FDA states that currently Tri-Luma is the only FDA-approved drug containing hydroquinone. According to Drugs@FDA, Tri-Luma is a prescription cream of fluocinolone acetonide 0.01%, hydroquinone 4% and tretinoin 0.05%. The FDA separately states that since enactment of the CARES Act, OTC skin lightening products containing hydroquinone are deemed to be new drugs and are misbranded.
Both DailyMed records above carry the unapproved status, so neither is an approval. The FDA also states that compounded drugs are not FDA-approved, which means FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.
What this does not tell you
The sources used here report no trial of hydroquinone 8% or of the four-ingredient blend with tretinoin, niacinamide and vitamin C, so findings at 4% or in other combinations cannot be assumed to apply. None of the sources above compares efficacy or irritation between strengths, so they give no measured basis for saying a higher strength changes either.
The ochronosis review rests on case reports, which cannot show cause and effect or how often the condition occurs. The 2015 review states an expectation. The 22-case figure has no concentration breakdown. A DailyMed listing shows that a product is listed and under what status. It does not show how the product performs. A licensed provider decides whether any strength suits a person.